Abstract
Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.
| Original language | English |
|---|---|
| Pages (from-to) | 229-235 |
| Number of pages | 7 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/metabolism
- Carcinoma, Non-Small-Cell Lung/classification
- Chemotherapy, Adjuvant/methods
- Clinical Trials as Topic
- Humans
- Lung Neoplasms/classification
- Neoadjuvant Therapy/methods
- Neoplasm Staging
- Recurrence
Fingerprint
Dive into the research topics of 'Neoadjuvant chemotherapy in early-stage non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver